Literature DB >> 9385419

Fixation-off, scotosensitive, and other visual-related epilepsies.

C P Panayiotopoulos1.   

Abstract

FOS is a relatively recently described specific mode of precipitation of seizures and paroxysmal EEG abnormalities. Elimination of central vision and fixation, even in the presence of light, induces high-amplitude occipital or generalized paroxysmal discharges. FOS is suggested on routine EEG by abnormalities that consistently occur as long as the patient's eyes are closed but not when the eyes are open. The model example of FOS is early-onset and late-onset BCEOP. Idiopathic and cryptogenic generalized epilepsies with FOS have been described. Scotosensitive epilepsy implies seizures and EEG abnormalities induced by the complete elimination of retinal light stimulation, and most cases described as scotosensitive are probably FOS. FOS has characteristics opposite to those of photosensitive epilepsies, but conversion from one to the other or co-existence may rarely occur. The underlying mechanisms of FOS are not known, but they may be related to an abnormality of the alpha-rhythm generators.

Entities:  

Mesh:

Year:  1998        PMID: 9385419

Source DB:  PubMed          Journal:  Adv Neurol        ISSN: 0091-3952


  3 in total

Review 1.  Photo-Dependent Reflex Seizures-A Scoping Review with Proposal of Classification.

Authors:  Jolanta Strzelecka; Dariusz Wojciech Mazurkiewicz; Tymon Skadorwa; Jakub S Gąsior; Sergiusz Jóźwiak
Journal:  J Clin Med       Date:  2022-06-29       Impact factor: 4.964

2.  Coexistence of fixation-off sensitivity and inverted fixation-off sensitivity in a female child with Panayiotopoulos syndrome: Video-electroencephalography documentation.

Authors:  Imad Y Saadeldin; Hussein N Matlik
Journal:  Epilepsy Behav Case Rep       Date:  2015-05-28

Review 3.  Electroencephalography in the Diagnosis of Genetic Generalized Epilepsy Syndromes.

Authors:  Udaya Seneviratne; Mark J Cook; Wendyl Jude D'Souza
Journal:  Front Neurol       Date:  2017-09-25       Impact factor: 4.003

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.